Epilepsy, a chronic neurological disorder characterized by recurrent, unprovoked seizures, poses significant challenges to healthcare professionals. Despite the availability of numerous antiepileptic drugs (AEDs), about one-third of patients continue to experience uncontrolled seizures. This article aims to provide an update on the latest advancements in epilepsy management.
The last decade has seen the introduction of several new-generation AEDs. These drugs, such as perampanel and brivaracetam, have demonstrated improved efficacy and tolerability. They act on novel targets, thus providing additional therapeutic options for patients with drug-resistant epilepsy. However, their long-term safety profiles remain to be fully established.
Neuromodulation therapies, such as Vagus Nerve Stimulation (VNS), Deep Brain Stimulation (DBS), and Responsive Neurostimulation (RNS), have emerged as effective adjunctive treatments for drug-resistant epilepsy. These therapies modulate neuronal activity, thereby reducing seizure frequency and severity. While invasive, they offer substantial benefits for patients who are not surgical candidates or have failed epilepsy surgery.
Advances in genetic testing have revolutionized the diagnostic approach to epilepsy. By identifying the genetic basis of certain epilepsy syndromes, healthcare professionals can provide more personalized treatment plans. These advancements also hold promise for the development of targeted therapies.
Telemedicine has emerged as a vital tool in epilepsy management, particularly amidst the COVID-19 pandemic. It allows for remote patient monitoring, reducing the need for hospital visits, and facilitating timely intervention. Moreover, it enables wider access to specialized epilepsy care, especially for patients in remote areas.
Advancements in epilepsy management are transforming the landscape of patient care. While challenges remain, these innovations offer hope for improved seizure control and quality of life for patients with epilepsy. Healthcare professionals must stay abreast of these developments to provide optimal patient care.
1.
A smartphone app enhances the tracking of recovery following breast and gynecologic oncology surgery, according to JAMA.
2.
Mezigdomide Combinations Show Promise in Multiple Myeloma
3.
Adult survivors of childhood cancer are at high risk for cognitive impairment, according to JAMA.
4.
Both DNA damage repair deficiency and non-Hodgkin lymphoma are the focus of LP-284.
5.
Oleanolic acid from grapes may increase chemotherapy effectiveness
1.
Advanced Approaches in Oncology and Patient Outcomes
2.
Unraveling the Mysteries of Hematocrit: How It Impacts Your Health
3.
Emerging Advances in Hematology and Quality Improvement
4.
The Silent Signs: Uncovering Stomach Cancer Symptoms Before It's Too Late
5.
Pembrolizumab Plus Lenvatinib in EBV-Associated Advanced Intrahepatic Cholangiocarcinoma: Case Study
1.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
2.
International Cancer Conference
3.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
4.
Asian Symposium on Advancement in Hematology and Oncology
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part IV
2.
Treatment Sequencing Strategies in ALK + NSCLC Patients with CNS Diseases - Part II
3.
Navigating the Complexities of Ph Negative ALL - Part XIV
4.
An Eagles View - Evidence-based discussion on Iron Deficiency Anemia- Important Points to Know
5.
Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part VIII
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation